Secretory IgA

Secretory immunoglobulin A is usually shortened to sIgA. It helps keep microbes and toxins from attaching to the gut lining and helps maintain your relationship with the bacteria that live there. Stool testing measures the antibody remaining in a sample after secretion, binding and breakdown in the gut. That concentration doesn't directly measure how well you're protected from infection.

Stool sIgA remains an exploratory clinical marker. Studies have found differences in people with antibody disorders and several gut conditions, but there are no universally standardized clinical cutoffs or validated targets for prevention. Testing healthy people, establishing personal baselines and adjusting treatment to this number haven't been shown to improve health outcomes.

What the Number Represents

Antibody-producing cells in the gut wall make IgA, usually as two antibody units joined by a linking protein. Cells lining the intestine transport it into the gut and release it with part of the transport protein attached. This attached piece is called the secretory component. It helps protect the antibody from digestive enzymes and supports its interaction with mucus.

sIgA can bind microbes, block their attachment to the gut wall and neutralize toxins while limiting inflammatory reactions. It also interacts with harmless resident bacteria. Finding IgA-coated bacteria therefore doesn't mean those bacteria are causing disease.

This test uses ELISA, an antibody-based laboratory method. ELISA names a method, not a single assay. The reporting units, which forms of IgA the assay detects, the extraction procedure and any comparison range depend on the performing laboratory. Many stool assays report micrograms per gram of stool, written as mcg/g. The result is a concentration in stool, not the amount your intestine produces each day. Stool water content, antibody breakdown and the laboratory's extraction procedure can affect that concentration.

Several measurements appear together in this research: secretory IgA, total stool IgA, antibodies directed against a particular germ, and the proportion of bacteria coated with IgA. They answer different questions. An ELISA that detects IgA without checking its secretory component can include other forms of IgA, so a study using total stool IgA isn't direct validation of a secretory IgA assay.

IgA Deficiency and Other Antibody Disorders

Selective IgA deficiency is diagnosed through blood testing. Blood and intestinal findings can differ: in a small study of children with blood-defined deficiency, some still had detectable stool IgA. Children lacking stool IgA had more evidence of immune disturbance. These were observational findings in a small group. They don't establish that a stool sIgA result predicts an individual's complications.

Other work found altered gut bacterial communities in people with IgA deficiency despite increased intestinal IgM. IgM is another antibody that can partly compensate for missing IgA. In common variable immunodeficiency, lower fecal IgA and IgM were associated with lower bacterial diversity. These studies also measured fecal immunoglobulins rather than validating any particular secretory IgA assay. Neither condition can be diagnosed from stool sIgA alone.

A registry study of blood-defined IgA deficiency found about a two-thirds higher rate of gastrointestinal cancer than in matched controls. The excess rate of cancer overall was greatest in the first year after diagnosis, which may partly reflect closer medical investigation. When that first year was excluded, the gastrointestinal cancer association was no longer statistically significant. This finding doesn't establish cancer risk from a stool antibody concentration.

Inflammatory Bowel Disease

In a study including 294 people, soluble total IgA and IgG in stool were higher in active Crohn's disease and ulcerative colitis and correlated with measures of disease activity. The study compared groups and used total IgA assays. It didn't establish that serial secretory IgA testing reliably tracks flares or treatment response.

A separate study found lower total fecal IgA in people with Crohn's disease in remission. Human tissue studies found abnormalities in the gut's antibody-producing cells, while experiments in cultured cells and mice supported a possible role for impaired cellular energy production. The stool assay measured total IgA, so describing this as a proven reduction in secretory IgA would go beyond the measurement.

Another research method separates bacteria according to whether IgA coats them. It identified bacterial groups more heavily targeted in inflammatory bowel disease, with some coating patterns associated with the later disease course. A total stool sIgA concentration doesn't identify those bacterial targets.

These findings explain why a higher number isn't automatically better and a lower number isn't automatically worse. They don't provide a reliable way to distinguish inflammation, infection or antibody deficiency from the stool concentration. Calprotectin and lactoferrin have substantially stronger evidence for assessing intestinal inflammation.

Gut Infections

An older study found more than twice as much total fecal IgA in people with diarrhea as in healthy controls. It used electroimmunodiffusion, a different laboratory method, and didn't establish that diarrhea was always caused by infection. That finding can't be used to diagnose an infection from this ELISA result.

Evidence about protection is often specific to one organism. Among 442 children in Bangladesh, higher stool IgA against a Cryptosporidium protein at age one was associated with a longer time until the next infection. Blood IgG against that protein didn't show the same association. This was a germ-specific antibody measurement, so its findings don't tell you how much total stool sIgA would protect you.

Transplant Recipients

Research in children with organ transplants found altered IgA targeting of gut bacteria, and that altered targeting was associated with long-lasting changes in their gut bacterial communities. Which bacteria are coated is a different measurement from a total stool concentration. The study doesn't establish what a single stool sIgA result means for a transplant recipient.

Why Blood and Intestinal Findings Can Differ

In an older study of severe alcohol-related cirrhosis, blood sIgA was high while antibody secretion into the small intestine was reduced. The intestinal measurement came from fluid collected directly from the intestine, using methods different from stool ELISA.

A later study associated higher blood sIgA with worse survival in acute-on-chronic liver failure. That was a blood finding in severe liver disease. It doesn't establish a prognostic meaning for a high stool result, and the processes producing high blood levels can't be inferred from stool testing.

Infant Findings Need Their Own Context

Breast milk contributes sIgA directly to an infant's gut, so an infant's stool result can include maternal antibody as well as antibody the infant produces. Feeding method and developmental stage are part of the interpretation.

Necrotizing enterocolitis is a serious bowel disease affecting mainly premature infants. In a case-control study, infants who later developed it had lower total stool IgA beforehand. The difference in stool secretory IgA wasn't statistically significant. The finding therefore doesn't validate this test for predicting the disease.

In a Canadian birth cohort, infant stool sIgA alone wasn't associated with later non-allergic wheeze. An exploratory subgroup analysis found an association when higher sIgA occurred alongside a particular pattern of gut bacteria in infants who weren't exclusively breastfed. The estimate was unadjusted and imprecise.

Other analyses associated depressive symptoms during pregnancy with lower infant stool sIgA, while stool sIgA didn't significantly explain associations between gut microbial products and later cognitive scores. These observations don't establish causation or provide useful individual predictions from a commercial stool result.

Celiac Disease Requires Different Tests

Total stool sIgA doesn't identify celiac disease. Even stool tests designed to detect IgA against specific celiac-related targets performed poorly in a pediatric validation study: the tissue transglutaminase version detected about one in ten cases. Those targeted tests are different from this total secretory IgA measurement. Established celiac evaluation uses blood antibodies and, when indicated, intestinal biopsy.

When Results Can Be Misleading

• Assay specificity: ELISA describes a method, not a single standardized test. Measuring secretory IgA requires distinguishing it from other IgA. Results from an assay that measures total IgA aren't interchangeable with a secretory-specific result.
• Extraction, dilution and calibration: laboratories can extract different amounts of antibody from the same stool and use different standards. Matching units doesn't make results from different assays equivalent.
• Stool consistency and handling: water content affects a result expressed per gram of stool. Collection, transport and storage outside the laboratory's instructions can also affect the sample.
• Illness and treatment changes: diarrhea, infection and changes in supplements or treatment can change the context of a result. They don't provide a reliable explanation for any particular high or low value.
• Age and feeding: breast milk contributes antibody to infant stool. Small adult observational analyses have also found age-related differences, but they don't establish an age threshold or a correction that can be applied to your result.
• Very low results: a result below an assay's reporting limit means the laboratory couldn't reliably quantify the antibody under that method. It doesn't prove that your intestine produces none.

What Serial Results Can Establish

A repeat result can show whether a finding persists under comparable collection and laboratory conditions. There isn't a validated change threshold that separates ordinary variation from a clinically meaningful change in stool sIgA. A rising or falling concentration alone doesn't establish improvement, deterioration or a need for treatment.